Related Experiment Video
Updated: Feb 5, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
NSAIDs may prevent EGFR-TKI-related skin rash in non-small cell lung cancer patients
Objectives:
Skin rash is a common adverse event induced by epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). Here, we aimed to predict factors that reduce EGFR-TKI-related skin rash.
Materials And Methods:
We conducted a single-center, retrospective study to predict factors that reduce skin rash in patients undergoing treatment for non-small cell lung cancer (NSCLC) with EGFR-TKIs using Cox proportional hazards model.
Results:
Cox proportional hazard analysis revealed that coadministration of non-steroidal anti-inflammatory drug (NSAID) had protective effects against rash. Steroid coadministration showed a trend to being effective in reducing rash.
Conclusion:
NSAIDs may be useful in preventing EGFR-TKI-related skin rash. .
Related Concept Videos
Cancer Prevention
Some...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Lung Capacity
Prevention of Further Absorption of Poison
Preventive Healthcare Services
Renewal of Skin Epidermal Stem Cells

